US2019151342A1PendingUtilityA1
Compositions that include anthocyanidins and methods of use
Est. expiryOct 21, 2029(~3.2 yrs left)· nominal 20-yr term from priority
A61P 37/04A61P 37/02A61P 35/00A61P 37/00A61P 39/02A61P 43/00A61P 3/10A61P 37/06A61P 37/08A61P 31/04A61P 31/12A61P 3/00A61P 29/00A61P 3/04A61P 31/00A61K 9/4866A23L 33/105A61K 45/06A23V 2002/00A61K 31/41A61K 9/4875A61K 31/365A61K 31/22A61K 31/7048A61P 17/02A61K 38/13A61K 31/341A61K 31/216A61K 9/4816A61K 31/352
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The compositions described herein and featured in the present invention include those that comprise anthocyanidin combinations rich in delphinidins, including delphinidins such as the ones found in berries. The compositions can optionally include either compositions that comprise andrographolides, such as the ones found in a plant of the genus Andrographis , or compositions that comprise combinations of myrtillin, quercetin, or caffeoyl quinic derivatives and proanthocyanidins, such as the ones found in the herba of a plant of the genus Vaccinium.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A composition comprising anthocyanins and/or anthocyanidins wherein
(a) about 35% of the composition, by weight, is an anthocyanin or anthocyanidin, (b) at least 15% of the anthocyanins and/or anthocyanidins, by weight, are sugar-free or sugar-containing delphinidins, (c) the composition is formulated as an extract obtained from Aristotelia chilensis plant and (d) the composition comprises the following content of anthocyanidins:
6.38% of delphinidin-3-O-sambuboiside-5-O-glucoside,
13.64% of delphinidin-3,5-O-diglucoside,
3.36% of cyanidin 3-O-sambubioside-5-O-glucoside,
1.58% of cyanidin-3,5-O-diglucoside,
1.67% of delphinidin-3-O-sambubioside,
6.95% of delphinidin-3-O-glucoside,
0.79% of cyanidin-3-O-sambubioside and
1.05% of cyanidin-3-O-glucoside.
2 . The composition according to claim 1 , further comprising an andrographolide, preferably, wherein the andrographolide constitutes, by weight, at least 10% of the composition, or wherein the andrographolide is an andrographolide, a deoxy-andrographolide, a neoandrographolide or a mixture thereof, or wherein the andrographolide is contained within an extract of a plant of the genus Andrographis , or wherein the ratio of anthocyanin and/or anthocyanidin to andrographolide is from 1.0:0.5 (w:w) to 1.0:2.5 (w:w).
3 . The composition according to claim 1 , wherein (a) the anthocyanins and/or anthocyanidins comprises myrtillin, quercetin or cyanidin, or (b) the composition further comprises a composition rich in myrtillin, quercetin and/or cyanidin, preferably, the composition rich in myrtillin, quercetin and/or cyanidin comprises at least 15% of myrtillin, quercetin and/or cyanidin.
4 . The composition according to claim 1 , wherein the composition is formulated for oral consumption or oral administration.
5 . A method of maintaining immune function in a subject, wherein the subject has no overt condition known to compromise the immune system which comprises administering a composition as claimed in claim 1 to a patient in need thereof in an amount and for a time sufficient to maintain immune function.
6 . A method according to claim 5 , wherein the subject is a human or the subject is an animal kept as a domestic pet or as livestock.
7 . A method of treating a patient who has a condition in which the immune system is undesirably suppressed, which comprises administering a composition as claimed in claim 1 to a patient in need thereof in an amount and for a time sufficient to stimulate the patient's immune system, or the condition is cancer or an acquired immunodeficiency syndrome.
8 . A method of treating inflammation in a subject, which comprises administering a composition as claimed in claim 1 to a patient in need thereof in an amount and for a time sufficient to reduce or improve a sign or symptom of inflammation in the subject, or the inflammation is caused by a burn or other traumatic injury, a chemical irritant or toxin, an infection, or an autoimmune disease, preferably the infection is a bacterial or viral infection.
9 . A method of treating metabolic syndrome in a patient, which comprises administering a composition as claimed in claim 1 to a patient in need thereof wherein the composition is administered in an amount and for a time sufficient to reduce or improve a sign or symptom of metabolic syndrome in the patient, or the metabolic syndrome is associated with diabetes.
10 . A pharmaceutical composition comprising (a) a first composition comprising a carrier and (b) 100 mg to 400 mg of a second composition wherein
(1) about 35% of the composition, by weight, is an anthocyanin or anthocyanidin, (2) at least 15% of the anthocyanins and/or anthocyanidins, by weight, are sugar-free or sugar-containing delphinidins, (3) the composition is formulated as an extract obtained from Aristotelia chilensis plant and (4) the composition comprises the following content of anthocyanidins:
6.38% of delphinidin-3-O-sambuboiside-5-O-glucoside,
13.64% of delphinidin-3,5-O-diglucoside,
3.36% of cyanidin 3-O-sambubioside-5-O-glucoside,
1.58% of cyanidin-3,5-O-diglucoside,
1.67% of delphinidin-3-O-sambubioside,
6.95% of delphinidin-3-O-glucoside,
0.79% of cyanidin-3-O-sambubioside and
1.05% of cyanidin-3-O-glucoside.
11 . The pharmaceutical composition of claim 10 , further comprising a third composition comprising an andrographolide, preferably about 30-40% of the third composition is an andrographolide.
12 . A pharmaceutical composition according to claim 10 , further comprising (c) a third composition comprising caffeeoylquinic acid.
13 . A method of making a composition of claim 1 , wherein the method comprises:
(a) providing a plant of Aristotelia chilensis comprising anthocyanins and/or anthocyanidins; (b) disrupting the integrity of the plant; (c) extracting chemicals from the disrupted plant to produce an extraction liquid; (d) concentrating the extraction liquid to produce an extraction mixture; (e) alkalinizing the extraction mixture; (f) separating at least one component in the extraction mixture from other components in the extraction mixture; and (g) collecting and drying at least one of the separated components.Join the waitlist — get patent alerts
Track US2019151342A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.